ID | 1199 |
Name of the vaccine | SC602 |
Microbe | Bacteria |
Disease name | Bacillary Dysentery (Shigellosis) |
Name of bacteria | Shigella genus |
Type of vaccine | Live attenuated |
Nucleic acid content | DNA |
Age | NA |
Description of the vaccine | Shigella flexneri 2a strain SC602. |
Name of the manufacturer | Institut Pasteur |
Name of the manufacturing country | NA |
Year of manufacture | NA |
Clinical Phase status | Clinical |
Bacterial strain | Gram-negative bacteria. |
Efficacy | NA |
Vaccine formulation | Lyophilized |
Dosage | Single dose. |
Mechanism of action | IgA ASC response and a threefold or greater rise in serum IgA antibody, urinary sIgA responses in addition to IgG ASC and IgG serum responses. |
Route of administration | Ingestion |
Indications | Protection against fever and severe shigellosis. |
Export | NA |
Approval | Conducted under Food and Drug Administration investigational new drug application. |
Adjuvant | NA |
Repurposing | NA |
Side effects of vaccine | Abdominal cramps, nausea, emesis, tenesmus, gas, headache, myalgia, arthralgia, loss of appetite and fatigue. |
Post vaccination | NA |
Dose type | Single dose |
Interspecies transfer | NA |
PubMed identifier | 10377124 |
Clinical trial number | NA |
Reference | http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=259&keywords= |
Other name | NA |
Additional Links | NA
|